What is Zymeworks?
Zymeworks Inc. operates as a global biotechnology leader dedicated to the discovery, development, and commercialization of next-generation biotherapeutics. The company distinguishes itself through its proprietary antibody engineering platforms, which allow for the creation of highly specific and potent therapeutic agents. By integrating these technical capabilities with a strategic approach to asset management, Zymeworks effectively bridges the gap between early-stage research and clinical-grade medical solutions. Its market position is defined by a commitment to addressing complex diseases, including cancer and various autoimmune disorders, where traditional treatment modalities have historically fallen short. Through strategic partnerships and internal innovation, the firm maintains a dual focus on long-term value creation and the delivery of life-saving medical interventions.
How much funding has Zymeworks raised?
Zymeworks has raised a total of $819.8M across 13 funding rounds:
Multiple Rounds
$22.3M
Multiple Rounds
$34.4M
Series A
$61.5M
Stock Offering
$63.6M
Stock Offering
$97.8M
Stock Offering
$201.3M
Stock Offering
$320.8M
Unspecified (2014): $1M supported by Undisclosed
Share Placement (2014): $17.3M featuring Undisclosed
Corporate Investment (2014): $4M backed by Fonds de Solidarité FTQ
Unspecified (2015): $8.6M with participation from Undisclosed
Unspecified (2015): $24M led by Undisclosed
Unspecified (2015): $1.8M supported by Undisclosed
Series A (2016): $61.5M featuring Fonds de Solidarité FTQ, Eli Lilly & Company, Celgene, CTI Life Sciences Fund, Brace Pharma Capital, Merlin Nexus, BDC Capital, Northleaf Venture Catalyst Fund, Lumira Capital, Perceptive Advisors, and Teralys Capital
Stock Issuance/Offering (2017): $63.6M backed by Undisclosed
Stock Issuance/Offering (2018): $97.8M with participation from Undisclosed
Stock Issuance/Offering (2019): $201.3M led by Undisclosed
Stock Issuance/Offering (2020): $320.8M supported by Undisclosed
Key Investors in Zymeworks
CTI Life Sciences Fund
A prominent Canadian biotech venture capital firm that focuses on catalyzing innovative ideas and assets into scalable biotech companies, emphasizing long-term value creation.
Perceptive Advisors
A New York-based investment firm managing significant assets, specifically focused on funding innovative healthcare and life sciences technologies.
Brace Pharma Capital
An investment firm dedicated to supporting innovative therapies for diseases with significant unmet medical needs, aiming to improve patient outcomes through strategic healthcare financing.
What's next for Zymeworks?
Looking ahead, the strategic deployment of the $320.8M will likely focus on scaling the company's clinical trial infrastructure and enhancing its internal R&D capabilities. As Zymeworks matures, the emphasis will shift toward the successful execution of late-stage clinical programs and the potential expansion of its licensed healthcare assets. The company is well-positioned to capitalize on its existing intellectual property, with a clear trajectory toward becoming a dominant player in the biopharmaceutical industry. Future growth will be driven by the continued validation of its antibody platforms and the potential for new strategic collaborations that could further diversify its therapeutic pipeline and strengthen its competitive advantage in the global healthcare market.
See full Zymeworks company page
